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Abstract: VIS, a quantitative index of pressor support, has been shown
to be a predictor of morbidity and mortality in infants younger than six
months who underwent CPB. Data on its prognostic utility following
pediatric OHT are lacking. This study compared clinical outcomes in
children with diﬀerential VIS after pediatric OHT. A retrospective
cohort study of 51 consecutive heart transplants from 2004 to 2011 was
performed at a pediatric tertiary care facility. Peak VIS was computed
within initial 24 and 48 h after OHT and was weighted for peak dose
and administration of any or all of six pressors. Patients with peak VIS
≥ 15 constituted high VIS group. Children who persistently required a
higher magnitude of pressor support for the ﬁrst 48 h after OHT, as
reﬂected by high peak VIS, had signiﬁcantly longer ICU stay (30.2 vs.
15.9 days, p = 0.01), pressor (11.4 vs. 6.8 days, p = 0.02) and
ventilatory durations (12.4 vs. 5.9 days, p = 0.05), and higher rates of
short-term morbidities. Patients with longer CPB (213 vs. 153 min,
p = 0.005) time have higher peak VIS. High peak VIS at 48 h is an
eﬀective, yet simple clinical marker for adverse outcomes in pediatric
OHT recipients.
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Pediatric orthotopic heart transplantation is the
therapeutic option of choice for children with
end-stage congenital or acquired heart disease
(1). Advancements in medical therapy, reﬁne-
ments in surgical techniques, and availability of
mechanical circulatory support systems have
resulted in higher post-transplant survival rates
in recent decades (2–4). Despite this, early post-
operative morbidity and mortality continue to be
signiﬁcant following pediatric OHT (5–7).
Currently, there is only limited use of early
postoperative markers that reﬂect the clinical sta-
tus of the individual patient as well as predict out-
comes after pediatric cardiac surgery. Inotropic
score is one such objective clinical tool. It was
initially described by Wernovsky et al. to quantify
the extent of circulatory support that neonates
received after arterial switch operation (8). Since
then, several studies have used inotropic score as a
measure of disease severity (9–11). More recently,
a modiﬁcation of this scoring system called the
vasoactive–inotropic score (VIS) was validated as
a predictor of outcome after pediatric cardiac sur-
gery (12, 13). VIS is a quantitative index of pressor
support and takes into consideration use of milri-
none, norepinephrine, and vasopressin in addition
to dopamine, dobutamine, and epinephrine. Gaies
et al. showed that VIS was a predictor of morbid-
ity and mortality in infants younger than six
months who underwent CPB (12).
There are no data on the prognostic utility of
VIS following pediatric OHT. The aim of our
study was to compare clinical outcomes in
groups of children with diﬀerential VIS after
pediatric OHT. Our hypothesis was that a persis-
tently high VIS in the initial 48 h post-OHT
would be associated with higher morbidity and
mortality, relative to a low VIS.
Methodology
This was a retrospective study conducted at a sin-
gle center, Children’s Hospital of Michigan.
Approval for the study and for waiver of parental
Abbreviations: CHD, congenital heart disease; CPB, car-
diopulmonary bypass; ECMO, extracorporeal membrane
oxygenation; ICU, intensive care unit; OHT, orthotopic
heart transplant; VIS, vasoactive–inotropic score.
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consent and subject assent was obtained from the
Institutional Review Board at Wayne State Uni-
versity and research authorization from Chil-
dren’s Hospital of Michigan. The charts of all
patients, 18 yr or younger, who underwent OHT
between 2004 and 2010 at our institution were
reviewed. Demographic, clinical, and immediate
postoperative outcome data were collected.
Demographic data included age, gender, diagno-
sis, and list status at the time of OHT. Preopera-
tive clinical data pertaining to requirement of
inotropic support, mechanical ventilation, or
mechanical circulatory support in the immediate
pretransplant period were also collected. Intraop-
erative characteristics including surgical tech-
nique of OHT, CPB time, and graft ischemia time
were abstracted. Implantation of the donor heart
was performed orthotopically using the biatrial
or the bicaval technique. Before being weaned oﬀ
CPB, patients were started on vasoactive medica-
tions by the attending anesthesiologist/surgeon.
The graft ischemic time was deﬁned in the study
as the time interval between the application of
aortic cross-clamp in the donor and the removal
of aortic cross-clamp in the recipient. In our cen-
ter, rewarming is started only after the aortic
cross-clamp is removed. Hence, the ischemic time
in this study only includes the cold ischemic phase
with temperatures maintained below 30 °C. In
the postoperative period, patients received close
hemodynamic monitoring in the pediatric ICU
with pulse oximetry, central venous pressure, left
atrial pressure, and arterial pressure.
Vasoactive infusions were titrated, changed, or
discontinued at the discretion of the cardiotho-
racic surgeons and pediatric intensivists based on
individual clinical scenarios. Initial choices for
vasoactive medication were milrinone, dobuta-
mine, and dopamine. Epinephrine, norepineph-
rine, and vasopressin were used as second-line
vasoactive agents. The doses of all the vasoactive
infusions were obtained from the ﬂow sheets at
three hourly intervals for up to 48 h post-trans-
plant. VIS was calculated using the formula
proposed by Gaies et al. (12).
VIS = dopamine (mcg/kg/min) + dobutamine
(mcg/kg/min) + 100 9 epinephrine (mcg/kg/min)
+ 100 norepinephrine (mcg/kg/min) + 10 9 mil-
rinone (mcg/kg/min) + 10 000 9 vasopressin
(mUnits/kg/min)
The VISs that were attained at three hourly
intervals during the ﬁrst 24 h and between 24–
48 h post-transplant were computed. A VIS of
15 or above on two or more of eight readings
was taken as high inotropic requirement (high
VIS 24 h). VIS of <15 at all time points of obser-
vation was considered to be low inotropic
requirement (low VIS 24 h). The cutoﬀ of peak
VIS of 15 was predetermined based on the ﬁve-
group classiﬁcation system proposed by Gaies
and colleagues (12). According to the authors, a
moderate cardiovascular support on admission
to the ICU after congenital heart surgery typi-
cally includes vasoactive infusions at dosages
that result in a VIS of approximately 15. We
required this cutoﬀ to be exceeded on two or
more occasions (representing 3-h period each)
over 24 h. Further analysis was performed com-
paring patients with persistent high VIS (48 h),
deﬁned as peak VIS > 15 on two or more read-
ings in each of the two 24-h periods (0–23 h, 24–
48 h after OHT), and all others, low VIS (48 h).
A standard protocol was followed for immu-
nosuppression post-OHT. All patients received
induction therapy with intravenous thymoglobu-
lin for ﬁve days. High-dose methyl prednisolone
was initiated intraoperatively and continued for
a total of six doses. Maintenance immunosup-
pressive regimen included tacrolimus, mycophen-
olate mofetil, and tapering dose of oral steroids.
Decisions regarding the immunosuppressive
therapy were made by the attending transplant
cardiologist.
The primary outcome variable for our study
was the total length of ICU stay after OHT. Sec-
ondary outcome variables included post-trans-
plant requirement of mechanical circulatory
support, duration of mechanical ventilation,
number of days on vasoactive infusions, acute
renal failure necessitating renal replacement
therapy, and death prior to initial discharge after
OHT.
Statistics
All data were reported as mean and standard
deviation (s.d.) for continuous variables and
frequency (percent) for categorical variables.
The two groups (high and low VIS 24 h and
persistent high and low VIS 48 h) were com-
pared using independent sample t-test, Fisher’s
exact test, or chi-square test depending on the
distribution of the data. Regression analysis was
performed to examine the association between
ICU stay and high VISs, after adjusting for
potential confounders found to be signiﬁcant on
univariate analysis. Statistical analyses were
performed using SPSS version 17 (SPSS Inc.,
Chicago, IL, USA).
Results
A total of 55 patients underwent OHT at our
institution from January 2004 to December 2010.
Of these, four patients were older than 18 yr at
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the time of OHT and were excluded from the
study. The median age at the time of OHT of our
study cohort (N = 51) was 1.3 yr (range: 1 wk–
17.9 yr). Of these, 25 (49%) were males. Based
on the listed ethnicity, 21 (42%) were Caucasian,
26 (51%) African American, one (2%) Hispanic,
and two (4%) were Asian. The indication for
OHT was CHD in 20 (39%), cardiomyopathy in
29 (57%), and tumor in two (4%) patients. The
list status was 1A in 46 (90%) patients at the time
of OHT. Prior to OHT, mechanical circulatory
support was required in 13 (26%) patients, of
which nine were on left ventricular assist device
and four on ECMO.In the pretransplant period,
14 (28%) patients were mechanically ventilated
and 30 (60%) required inotropic support. The
computed VIS ranged from 3 to 48, with a med-
ian of 14 in the 0- to 24-h period and 12 in the
24- to 48-h period after OHT.
Initial 24 h post-OHT
In the ﬁrst 24 h after OHT, 28 (55%) patients
had peak VIS of 15 or more on two or more
occasions and were categorized as high VIS
(24 h) group. The 23 (45%) patients, who had
VIS of <15, comprised the low VIS (24 h) group.
On comparing the groups, the low VIS (24 h)
group tended to have a predominance of cardio-
myopathy rather than CHD. Demographic data
including age, gender, ethnicity, and list status at
the time of OHT were similar among the groups
(Table 1). Preoperative requirements of mechani-
cal ventilation, inotropic support, or mechanical
circulatory support were also not diﬀerent
between the groups.
Table 2 compares operative characteristics
and outcome among the two groups. A biatrial
approach was used for OHT in 22 patients each
(79% vs. 96%, p = 0.08) in the high and low
VIS (24 h) groups, respectively. Children in the
high VIS (24 h) group had signiﬁcantly longer
CPB time (188 min) than those in the low VIS
(24 h) group (148 min) (p = 0.03). The graft
ischemia time was similar between the groups.
The outcome variables including length of ICU
stay, duration of mechanical ventilation, and
duration of vasoactive therapy were not signiﬁ-
cantly diﬀerent between the groups. Acute renal
failure necessitating renal replacement therapy
was diagnosed in six patients in the high VIS
(24 h) group, compared with one patient in the
low VIS (24 h) group, a diﬀerence that did not
reach statistical signiﬁcance (p = 0.11). Post-
OHT ICU length of stay, death, and post-OHT
ECMO all tended to be higher in the high VIS
(24 h) group.
48 h post-OHT
Between 24–48 h after OHT, 15 patients contin-
ued to require high dose of vasoactive infusions.
These patients with a VIS of 15 or higher on two
or more occasions in the 24- to 48-h postopera-
tive period were categorized as persistent high
VIS (48 h) group. The remaining 36 patients
(71%) who had peak VIS <15 between 24 and
48 h after OHT constituted the low VIS (48 h)
group. All the patients with a low VIS in the ﬁrst
24 h post-OHT continued to require low inotro-
pic support in the subsequent 24 h.
On comparing the persistent high VIS (48 h)
group with low VIS (48 h) group (Table 3), the
only signiﬁcant diﬀerence was that in the
Table 1. Demographic and preoperative data of high and low vasoactive–ino-
tropic score groups at 24 h after orthotopic heart transplant
N (%)*
High VIS (24 h)
(N = 28)
Low VIS (24 h)
(N = 23) p-value
Age (yr) median (range) 1.1 (0.02–17.5) 1.2 (0.05–17.9) 0.61
Male 15 (54%) 10 (44%) 0.33
Ethnicity
Caucasian 10 (36%) 11 (48%) 0.39
African American 15 (53%) 11 (48%)
Hispanic 1 (4%) 0 (0%)
Asian 2 (8%) 1 (4%)
Status 1A 28 (100%) 21 (92%) 0.47
Diagnosis
CHD 14 (50%) 6 (27%) 0.09
Cardiomyopathy 14 (50%) 15 (65%)
Tumor 0 (0%) 2 (8%)
Preop mechanical
ventilation
7 (25%) 7 (30%) 0.46
Preop inotropic therapy 17 (60%) 13 (56%) 0.49
Preop LVAD/ECMO 9 (32%) 4 (18%) 0.46
*Value expressed as number (percentage).
CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenator;
LVAD, left ventricular assist device; OHT, orthotopic heart transplant; Preop,
preoperative; VIS, vasoactive–inotropic score.
Table 2. Comparison of intra-operative and outcome variables - 24 h after
orthotopic heart transplant
Mean (s.d.) or n (%)
High VIS (24 h)
(N = 28)
Low VIS (24 h)
(N = 23) p-value
Graft ischemia time (min) 191 (56) 195 (43) 0.76
CPB time (min) 188 (79) 148 (52) 0.03
Biatrial technique 22 (78%) 22 (95%) 0.08
Intensive care unit stay (days) 24 (22.5) 15.4 (10.8) 0.09
Mechanical ventilation (days) 9.6 (12.7) 5.6 (6.9) 0.17
Vasoactive infusion (days) 8.8 (8) 7.5 (4.2) 0.5
Post-op ECMO 3 (11%) 1 (5%) 0.61
Acute renal failure 6 (21%) 1 (5%) 0.11
Death 3 (11%) 1 (5%) 0.61
CPB, cardiopulmonary bypass; OHT, Post-op, postoperative; ECMO, extracorpo-
real membrane oxygenator; VIS, vasoactive–inotropic score.
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persistent high VIS (48 h) group, 67% of patients
underwent OHT for CHD compared with 27%
of the patients in the low VIS (48 h) group
(p = 0.01). Preoperative requirement of mechani-
cal ventilation, inotropic support, or mechanical
circulatory support was not diﬀerent between the
groups.
Comparison of the operative and outcome
data is detailed in Table 4. Biatrial technique
was used for OHT in the majority of patients in
both groups. Patients in the persistent high VIS
(48 h) group had signiﬁcantly longer CPB time
(213 [83] vs. 153 [57], p = 0.005). The persis-
tent high VIS (48 h) group patients required
longer duration of vasoactive infusion therapy
(p = 0.02), post-OHT ICU stay (p = 0.01), and
higher rate of renal failure (p < 0.001), compared
with low VIS (48 h) group. Three patients in the
persistent high VIS (48 h) group and one patient
in the low VIS (48 h) group required ECMO
support after OHT. This diﬀerence was not
statistically signiﬁcant.
The overall mortality rate in the immediate
post-transplant period was 7.8%. Three (20%)
subjects in the persistent high VIS (48 h) group
died compared with one (4%) in the low VIS
(48 h) group (p = 0.08). Cause of death was sep-
sis in two patients and multiorgan dysfunction in
the third patient in the persistent high VIS (48 h)
group and postoperative bleeding in the patient
in the persistent low VIS (48 h) group.
On regression analysis, with diagnosis (CHD
vs. cardiomyopathy), CPB time, persistent high
VIS at 48-h group, and mechanical circulatory
support prior to OHT as covariates, ICU stay
was signiﬁcantly associated with persistent high
VIS at 48-h group (p = 0.04). There was no sig-
niﬁcant association between ICU stay and any
other variables. High VIS at 24 h was not signiﬁ-
cantly associated with length of ICU stay.
Discussion
In this study, we evaluated the association
between VIS following OHT in children and
short-term outcomes. Our study shows that per-
sistently high VIS in the ﬁrst 48 h after pediatric
OHT is associated with short-term morbidities
such as renal failure, increased post-OHT length
of stay, and duration of pressor therapy.
Although not statistically signiﬁcant, death
tended to be higher in those with persistent high
VIS until 48 h. High VIS as deﬁned (more than
15 on ≥ 2 times three h apart in 24 h) was com-
mon (55%) in the initial 24 h after OHT and
does not appear to be associated with adverse
outcomes. A third of subjects continued to
require high dose of vasoactive agents in the
subsequent 24 h, high VIS (48 h) group. CHD
was the predominant underlying indication for
pediatric OHT in the persistent high VIS (48 h)
group.
Vasoactive inotropic score was initially pro-
posed by Gaies et al. (12). They evaluated 174
infants (age 0–6 months) undergoing cardiovas-
cular surgery with CPB and concluded that the
maximum VIS over the ﬁrst 48 h after cardiac
surgery was a good predictor of poor clinical
outcome such as death, cardiac arrest, mechani-
cal circulatory support, renal replacement, and/
or neurological injury. High VIS was strongly
associated with poor outcomes and length of
stay and duration of mechanical ventilation.
Table 3. Demographic and preoperative data: persistent high and low vasoac-
tive–inotropic score groups at 48 h after orthotopic heart transplant
N (%)*
High VIS (48 h)
(N = 15)
Low VIS (48 h)
(N = 36) p-value
Age (yr) median (range) 1.1 (0.02–17.9) 1.3 (0.04–17.9) 0.39
Male 7 (47%) 18 (50%) 0.53
Ethnicity
Caucasian 5 (33%) 16 (47%) 0.37
African American 8 (53%) 18 (50%)
Hispanic 1 (7%) 0 (0%)
Asian 1 (7%) 1 (3%)
Status 1A 14 (93%) 30 (83%) 0.76
Diagnosis
CHD 10 (67%) 10 (28%) 0.01
Cardiomyopathy 5 (33%) 24 (67%)
Tumor 0 (0%) 2 (5%)
Preop mechanical ventilation 5 (33%) 9 (25%) 0.54
Preop inotropic therapy 11 (73%) 19 (53%) 0.17
Preop LVAD/ECMO 4 (26%) 9 (25%) 0.07
*Value expressed as number (percentage).
CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenator;
LVAD, left ventricular assist device; OHT, orthotopic heart transplant; Preop,
preoperative; VIS, vasoactive–inotropic score.
Table 4. Comparison of intra-operative and outcome variables—persistent
high and low vasoactive–inotropic score groups at 48 h after orthotopic heart
transplant
Mean (s.d.) or n (%)
High VIS (48 h)
(N = 15)
Low VIS (48 h)
(N = 36) p-value
Graft ischemia time (min) 200 (56) 189 (48) 0.48
CPB time (min) 213 (83) 153 (57) 0.005
Biatrial technique 12 (80%) 32 (97%) 0.4
Intensive care unit stay (days) 30.2 (27.4) 15.9 (11.3) 0.01
Mechanical ventilation (days) 12.4 (15.7) 5.9 (10.2) 0.05
Vasoactive infusion (days) 11.4 (9.8) 6.8 (3.8) 0.02
Post-op ECMO 3 (20%) 1 (4%) 0.07
Renal failure 6 (40%) 1 (3%) <0.001
Death 3 (20%) 1 (4%) 0.07
CPB, cardiopulmonary bypass; Post-op, postoperative; ECMO, extracorporeal
membrane oxygenator; VIS, vasoactive–inotropic score.
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Davidson et al., in a study on 70 infants
(≤90 days of age) undergoing cardiothoracic sur-
gery found that a higher VIS at 48 h after car-
diothoracic surgery was strongly associated with
increased length of ventilation and prolonged
ICU and total hospital stay (13). Their results
also showed that high VIS at 48 h was better
than VIS maximum in predicting short-term
morbidity, suggesting that the duration, rather
than the intensity of pressor support, may be a
marker of adverse outcomes. Butts et al. studied
low cardiac output syndrome and maximum VIS
in neonates (n = 76) undergoing cardiac surgery
requiring CPB (14). They reported a moderate
association of increasing VIS with longer dura-
tion of mechanical ventilation as well as ICU
stay. Again maximum VIS did not correlate with
the total hospital length of stay.
All these previous studies on VIS have been on
neonates and infants up to 6 months of age. Our
study cohort included all patients <18 yr of age
at the time of transplant and had a median age
of 1.4 yr. This is the ﬁrst study to evaluate the
prognostic utility of VIS following pediatric
OHT.
We evaluated both the intensity of vasoactive
therapy and the duration for which high-inten-
sity therapy was required. Our study showed
that high VIS in the initial 24 h was quite com-
mon after OHT, speciﬁcally in those with longer
CPB time, but was not signiﬁcantly associated
with adverse short-term outcomes. We speculate
that high requirement of vasoactive agents in
the initial 24 h after OHT was probably due to
the transient circulatory changes secondary to
prolonged CPB. In contrast, a persistent high
VIS for 48 h may be a marker of worse underly-
ing physiology. These ﬁndings are similar to
those reported recently by other investigators.
(12–14).
Children undergoing OHT for CHD tended to
have high VIS (48 h) in this study. This goes
along with the ﬁndings from previous studies as
well (15–17). It has been shown that periopera-
tive morbidity in patients with CHD undergoing
OHT is higher when compared with patients with
cardiomyopathy undergoing OHT. Reoperation,
need for reconstructive procedures, high techni-
cal complexity of the surgical procedure,
increased pulmonary vascular resistance, and
allograft sensitization may all contribute to the
higher postoperative severity of illness in these
patients. Patients with CHD also have a signiﬁ-
cantly longer CPB time; however, neither diag-
nosis nor CPB time were independently
associated with postoperative length of stay
following OHT in our study.
Renal failure in the perioperative period has
been shown to be associated with increased mor-
tality and morbidity after OHT (18–20). Our
data suggest that there is a higher occurrence of
acute renal failure in patients persistently needing
high vasoactive support in the initial 48 h after
OHT. The association between high VIS and
postoperative renal failure may have physiologi-
cal plausibility—renal failure in this scenario is
often prerenal related to hypoperfusion of the
kidney. Further, renal failure may be a key factor
in the pathway to adverse outcomes such as
prolonged length of stay and death.
Persistent requirement of vasoactive agents as
shown by high VIS (48 h) may likely be a surro-
gate marker of disease severity, rather than the
cause of increased morbidity. However, there
have been a few studies which show that use of
vasopressin and dopamine in the immediate
postoperative period is associated with poor
short-term outcomes (21, 22).
The VIS is an objective measure of the level of
inotropic support and therefore severity of ill-
ness. This tool may have potential utility in the
comparison of VIS-adjusted outcomes across
transplant centers for research and clinical
improvement purposes. In addition, as a persis-
tent high VIS at 48 h is associated with longer
ICU stay and short-term adverse outcomes fol-
lowing OHT, it may be useful in counseling fami-
lies at an early time point. It is possible that a
high VIS, if validated in larger multicenter stud-
ies, may aid in risk stratiﬁcation for future trials
of therapeutic interventions in this population.
Study limitations
Our study is a retrospective review from a single
institution. Even though the sample size was
small, the pediatric OHT population is relatively
rare but homogenous. Due to the retrospective
nature, data collection depended on the extent of
documentation in the medical records. The clini-
cal management of patients was not protocol-
driven and may have varied based on the
judgment and practice of individual clinicians.
Our retrospective study was not intended to
investigate the causality between use of various
vasoactive agents and short-term morbidity
following OHT in children.
Conclusion
To our knowledge, this is the ﬁrst study compar-
ing outcomes of pediatric heart transplantation
based on the post-transplant VIS. This study
validates the use of VIS in pediatric OHT recipi-
ents. Persistent requirement of high doses of
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vasopressor and inotropes at 48 h post-OHT
(high VIS 48 h) is independently associated with
increased short-term morbidity after pediatric
OHT. Further prospective studies with stringent
protocols for inotrope management are required
to assess the role of VIS in predicting long-term
outcome and to evaluate a causal relationship, if
any, between high inotrope use and adverse
outcomes including mortality.
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